Octagon Capital Advisors’s Alpine Immune Sciences Inc ALPN Stock Holding History

Octagon Capital Advisors’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,241,300	Closed	-$49.2M	–	60
2024 Q1	$49.2M	Hold	1,241,300	–	–	5.9%	2
2023 Q4	$23.7M	Buy	1,241,300 +491,300	+66%	+$6.83M	3.79%	9
2023 Q3	$8.59M	Hold	750,000	–	–	1.32%	19
2023 Q2	$7.71M	Sell	750,000 -452,000	-38%	-$4.08M	1.07%	19
2023 Q1	$9.28M	Sell	1,202,000 -23,000	-2%	-$183K	1.34%	15
2022 Q4	$9M	Hold	1,225,000	–	–	1.4%	16
2022 Q3	$8.82M	Buy	+1,225,000	New	+$10.1M	1.52%	16

Octagon Capital Advisors's ALPN Position: Q2 2024 in Review

Octagon Capital Advisors sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 1,241,300 shares — an estimated $49.2M sold.

Octagon Capital Advisors first reported a position in ALPN in Q3 2022 and held it in 7 quarters. The position peaked at $49.2M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

Octagon Capital Advisors reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
Octagon Capital Advisors sold 1,241,300 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $49.2M.
Octagon Capital Advisors first reported a position in Alpine Immune Sciences Inc in Q3 2022 and held it in 7 quarters.
Octagon Capital Advisors's Alpine Immune Sciences Inc position peaked at $49.2M in Q1 2024.
0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.